Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA(TM) (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Stock Information for GTX Corp

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About GTX Corp

Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.